Cambridge Biotech Co-Founded by Alnylam Founder Files for U.S. IPO
A Cambridge-based biotech co-founded by Alnylam’s founder Maraganore filed for a U.S. IPO on September 25, 2026. Focused on RNA therapeutic platforms, the company has no product revenue and remains in preclinical development, seeking capital for R&D advancement.
51CFO view：For preclinical biotechs going public, the CFO must build a dual-track disclosure system: non-GAAP R&D capitalization + milestone accounting, plus full R&D cost allocation logic for auditors. If executives have China ties, the CFO must prep SEC-ready explanations on VIE structure and cross-border fund flows.
A Cambridge-based biotech co-founded by Alnylam’s founder Maraganore filed for a U.S. IPO on September 25, 2026. Focused on RNA therapeutic platforms, the company has no product revenue and remains in preclinical development, seeking capital for R&D advancement.
Source：Google News · 美股 IPO
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
Who runs finance through a SPAC merger?
De-SPAC files F-1 / 424(b); merger audit and disclosure cadence differ.
Read →
What to do 18 months before filing
Financial readiness: audit basis, internal control, equity restatement.
Read →